A diagnosis that already accounts for what can be said.
Brand, audiences, channels and competitors, analysed inside the real regulatory frame of the product and the market it will run in.
Why this rarely works
A healthcare strategy written without the regulatory frame produces a plan that collapses at first review. The most attractive territories tend to be exactly the ones that cannot be supported.
And there's a tension that rarely gets named: the medical audience and the patient audience need different messages, in different channels, under different permissions. Treating them as one public is the most expensive mistake in the category.
What's included
Digital presence diagnosis
Site, organic, paid, reputation and competitors. Whatever can't be measured for lack of access is declared as such, not estimated.
Audience and permission map
What can be said to each public — professionals, patients, caregivers, institutions — and in which channel saying it is allowed.
Positioning and territory
Who you actually compete with and which ground is vacant, assessed against what the product can support with evidence.
Roadmap with KPIs
What happens each month, on what budget, measured against which number, with a baseline taken before starting.
Why us
We're the ones who then have to execute that plan and take it through review. That stops us proposing territories that won't survive the MLR cycle — which is the usual reason a healthcare strategy ends up as an unexecuted deck.
Questions we get
Does this work if we already have a global agency with locked guidelines?
It's a common case and it works well: the work becomes local adaptation, which is exactly where global guidelines tend to collide with local regulation. We don't propose replacing what's already globally approved.
How long does it take?
The full diagnosis takes two to three weeks depending on how much access is granted. Positioning and roadmap, two more.
Do you work on products that aren't approved yet?
On disease awareness and education material, yes, and under stricter rules than an in-market product. Promotion of an unapproved product is not something we do, and that's a conversation we'd rather have on day one.
The other services
regulatory compliance
Medical and legal validation of every asset, by market and by brand, built into production instead of bolted on at the end.
See the service → 03medical and creative content
Educational and promotional content for professionals and patients, produced with the evidence up front and the craft intact.
See the service → 04omnichannel and engagement
Communication journeys for professionals and patients, coordinated across channels and measured end to end.
See the service → 05paid media and performance
Search, social and programmatic inside each platform's health policies, with no sensitive data ever entering a pixel.
See the service →